CureXcell employs activated white blood cells, obtained from young healthy donor blood, which are injected into the wound.
Clalit Health Services will offer the wound treatment cell therapy product, CureXcell developed by MacroCure Ltd. to patients with chronic wounds. MacroCure is a cell therapy portfolio company of Eli Hurvitz's Pontifax Fund.
Clalit says on its website that it is offering "an innovative treatment for chronic wounds, based on cells ability to heal themselves." Clalit will offer CureXcell for one month to patients with open wounds. CureXcell employs activated white blood cells, obtained from young (18-40 years old) healthy donor blood, which are injected into the wound.
CureXcell is undergoing clinical trials for US Food and Drug Administration (FDA) certification.
MacroCure was founded on research by Prof. David Danon on the Weizmann Institute of Science.
Published by Globes [online], Israel business news - www.globes-online.com - on August 9, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010